Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
Why this paper is included
Supporting source evidence:
This increased to 38% and 53% in the 16 and 48‐weeks post‐fracture, respectively. 24% already had a prescription for vitamin D/calcium which increased to 73% at 48‐weeks post‐fracture.
Source: Abstract. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Observational study.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Meta-analysis unclear · Blinding unclear / not reported · Human research reported
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
For this retrospective observational study, we used routinely‐collected general practice (GP) data within the Clinical Practice Research Datalink (CPRD) GOLD together with Office for National Statistics (ONS) mortality data.
Source: Methods.
Patients were included if they received a diagnosis of parkinsonism prior to or during the study period.
Source: Methods.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
Mind the Gap: Predictors of Osteoporosis Treatment Following Fragility Fracture in Parkinsonism
Observational study · Movement Disorders Clinical Practice · 2026
Original publication title
Mind the Gap: Predictors of Osteoporosis Treatment Following Fragility Fracture in Parkinsonism
© 2026 The Author(s). Movement Disorders Clinical Practice published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Original publication · Publisher record · CC BY 4.0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
Abstract: What objectives does the paper state?
Our objective was to study the extent to which osteoporosis was treated, and predictors of treatment in a large representative cohort with parkinsonism.
Source: ObjectivesAbstract: What methods does the paper describe?
The clinical practice research datalink (CPRD) GOLD data contains anonymized UK primary care data. We identified fragility fractures (hip, vertebrae, wrist/distal radius, humerus, rib, pelvis and unspecified osteoporotic) amongst prevalent parkinsonism patients between 2010 and 2019, and ascertained whether bone protective medications and/or vitamin D/calcium supplements were prescribed in the pre‐fracture period or in the 48‐weeks post‐fracture. Logistic regression was used to determine predictors of prescriptions.
Source: MethodsAbstract: Results
There were 21,581 people with parkinsonism (mean age 74.7 ± 9.8 years, 40% female), with a mean of 3.1 ± 2.5 years of available data. One thousand eight hundred twenty‐three experienced at least one fragility fracture. Prior to a fragility fracture 12% had a prescription for bone protective medication. This increased to 38% and 53% in the 16 and 48‐weeks post‐fracture, respectively. 24% already had a prescription for vitamin D/calcium which increased to 73% at 48‐weeks post‐fracture. Female gender (OR = 2.06 [1.69 to 2.51], p < 0.001) and sustaining a vertebral fracture (OR = 2.06 [1.53 to 2.77], p < 0.001) increased the odds of bone protection prescriptions.
However, sustaining a rib fracture (OR = 0.34 [0.19 to 0.60], p < 0.001) or residing in a care home (OR = 0.58 [0.38 to 0.88], p = 0.01) decreased the odds.
Source: ResultsAbstract: Conclusions
There is an osteoporosis treatment gap in Parkinson's rendering an already high‐risk population at further risk of fracture. Men and those with rib fractures are two groups who are least likely to receive potentially beneficial treatment.
Source: ConclusionsAuthors’ abstract
Abstract
Background
Fracture risk is increased in Parkinson's yet this risk is often not addressed.
Objectives
Our objective was to study the extent to which osteoporosis was treated, and predictors of treatment in a large representative cohort with parkinsonism.
Methods
The clinical practice research datalink (CPRD) GOLD data contains anonymized UK primary care data. We identified fragility fractures (hip, vertebrae, wrist/distal radius, humerus, rib, pelvis and unspecified osteoporotic) amongst prevalent parkinsonism patients between 2010 and 2019, and ascertained whether bone protective medications and/or vitamin D/calcium supplements were prescribed in the pre‐fracture period or in the 48‐weeks post‐fracture. Logistic regression was used to determine predictors of prescriptions.
Results
There were 21,581 people with parkinsonism (mean age 74.7 ± 9.8 years, 40% female), with a mean of 3.1 ± 2.5 years of available data. One thousand eight hundred twenty‐three experienced at least one fragility fracture. Prior to a fragility fracture 12% had a prescription for bone protective medication. This increased to 38% and 53% in the 16 and 48‐weeks post‐fracture, respectively. 24% already had a prescription for vitamin D/calcium which increased to 73% at 48‐weeks post‐fracture. Female gender (OR = 2.06 [1.69 to 2.51], p < 0.001) and sustaining a vertebral fracture (OR = 2.06 [1.53 to 2.77], p < 0.001) increased the odds of bone protection prescriptions.
However, sustaining a rib fracture (OR = 0.34 [0.19 to 0.60], p < 0.001) or residing in a care home (OR = 0.58 [0.38 to 0.88], p = 0.01) decreased the odds.
Conclusions
There is an osteoporosis treatment gap in Parkinson's rendering an already high‐risk population at further risk of fracture. Men and those with rib fractures are two groups who are least likely to receive potentially beneficial treatment.
Publication and source details
Original title: Mind the Gap: Predictors of Osteoporosis Treatment Following Fragility Fracture in Parkinsonism
Katie C. Naylor; Emily J. Henderson; Emma Tenison
Movement Disorders Clinical Practice · 2026
* Correspondence to: Katie C. Naylor, University of Bristol, Canynge Hall, Bristol, BS8 2PS, UK; E‐mail: katie.naylor@bristol.ac.uk© 2026 The Author(s). Movement Disorders Clinical Practice published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. Gatsby Charitable Foundation10.13039/501100000324 GAT3676
Repository JATS snapshot; version as supplied
Source retrieved: 2026-11-10T23:13:09.049507+00:00
DOI: 10.1002/mdc3.70652 · PMC13339595